Sympathetic Blockade with Botulinum Toxin Tied to Pain Relief in Complex Regional Pain Syndrome: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-03-01 03:30 GMT   |   Update On 2022-03-01 03:30 GMT
Advertisement

South Korea: Lumbar sympathetic ganglion block using botulinum toxin type A raised the temperature of the affected foot for 3 months in patients with complex regional pain syndrome and also reduced the pain, reveals a recent study. The study was published in the February 2022 issue of the journal Anesthesiology. 

The study was designed to test the hypothesis that botulinum toxin prolongs the duration of a lumbar sympathetic block measured through a sustained increase in skin temperature. Jee Youn Moon, Seoul National University Hospital, Seoul, Republic of Korea, and colleagues performed a randomized, double-blind, controlled trial to examine the clinical outcome of botulinum toxin type A for lumbar sympathetic ganglion block in patients with complex regional pain syndrome.

Advertisement

For this purpose, the researchers conducted lumbar sympathetic ganglion block in patients with lower-extremity complex regional pain syndrome using 75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic (control group). 

The change in the relative temperature difference on the blocked sole compared with the contralateral sole at 1 postoperative month was the primary outcome. The 3-month changes in relative temperature differences, and the pain intensity changes were the secondary outcomes. 

A total of 48 participants (N = 24/group) were randomly assigned. 

Based on the study, the researchers found the following:

  • The change in relative temperature increase was higher in the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ± 0.8, respectively), which was maintained at 3 months (1.1°C ± 0.8 vs. –0.2°C ± 1.2, respectively).
  • Moreover, pain intensity was greatly reduced in the botulinum toxin group compared with the control group at 1 month (–2.2 ± 1.0 vs. –1.0 ± 1.6, respectively) and 3 months (–2.0 ± 1.0 vs. –0.6 ± 1.6, respectively).
  • There were no severe adverse events pertinent to botulinum toxin injection.

"We found that compared with local anesthetic, injections of botulinum toxin type A onto the lumbar sympathetic ganglia increased temperature on the affected foot for 3 months," the authors wrote. This was accompanied by pain reduction and cold tolerance improvement. Moreover, it also improved aching and numbness." 

Reference:

Yongjae Yoo, Chang-Soon Lee, Jungsoo Kim, Dongwon Jo, Jee Youn Moon; Botulinum Toxin Type A for Lumbar Sympathetic Ganglion Block in Complex Regional Pain Syndrome: A Randomized Trial. Anesthesiology 2022; 136:314–325 doi: https://doi.org/10.1097/ALN.0000000000004084

Tags:    
Article Source : Anesthesiology journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News